Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
HPAC
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "HPAC" in MCE Product Catalog:
17
17 Publications Verification
Synonyms: RMC-6236; RAS-IN-2
Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
10
4
4 Cited Publications
BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research .
2
Category:
Disease Research Antibacterial Microorganisms Macrolide Antibiotics Antibiotics Phenols Polyphenols Anticancer Disease Research Fields Endocrinology
Target:
Cat. No.: HY-P99237
CAS No.: 1615692-28-8
Synonyms: MMUC 1206A
Cat. No.: HY-123009
CAS No.: 927823-01-6
Target:
HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase Apoptosis Carbonic Anhydrase VEGFR GLUT
Research Areas:
KCN1 is a p300/HIF-1α interaction inhibitor with a Kd value of 345 nM for p300-CH1. KCN1 binds to the CH1 domain of p300, blocks the assembly of the p300/HIF-1α complex, and disrupts the HIF-1α-p300/CBP interaction. KCN1 inhibits cancer cell growth, induces cancer cell cycle arrest and apoptosis. KCN1 inhibits β-galactosidase activity and downregulates the expression of VEGF, Glut1, CA9 and CAIX. KCN1 exerts anticancer activity in mouse tumor xenograft models. KCN1 can be used in research related to malignant glioma, pancreatic cancer and metastatic uveal melanoma .
Cat. No.: HY-P991229
Synonyms: AGS-1C4D4; AGS-PSCA
Target:
Research Areas:
Cat. No.: HY-158703
CAS No.: 3033701-29-7
KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC50 of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity .
Cat. No.: HY-163468
CAS No.: 2137490-93-6
SRC-3-IN-1 (compound SI-10) is a steroid receptor coactivator 3 (SRC-3) inhibitor (IC50=3.3 μM). SRC-3-IN-1 has good water solubility, oral bioavailability, and improved selectivity profile. SRC-3-IN-1 can be used in prostate cancer research .
Cat. No.: HY-RS09953
Target:
Research Areas:
PACC1 Human Pre-designed siRNA Set A contains three designed siRNAs for PACC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-172210
CAS No.: 3017180-18-3
Target:
Research Areas:
DDO-8958 is an orally active and selective BET BD1 inhibitor with a KD of 5.6 nM for BRD4 BD1. DDO-8958 exhibits low nanomolar inhibitory activity against all BET BD1 bromodomains except for BRDT BD1. DDO-8958 can inhibit the proliferation and migration, induce apoptosis and cell cycle arrest of tumor cells. DDO-8958 has anti-tumor activity .
Cat. No.: HY-158076
S2/IAPinh is a conjugate, which consist of an inhibitor for the apoptosis protein inhibitor (IAPinh) and a ligand for sigma 2 SW43. S2/IAPinh exhibits an anti-proliferative and apoptotic-inducing effect through degradation of the cellular inhibitor for apoptosis protein (clAP-1) .
Cat. No.: HY-180885S
Cat. No.: HY-P701388
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PSMG3; Proteasome assembly chaperone 3; PAC-3; HPAC3
Cat. No.: HY-P701390
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PSMG4; Proteasome assembly chaperone 4; PAC-4; HPAC4
Cat. No.: HY-P701389
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PSMG3; Proteasome assembly chaperone 3; PAC-3; HPAC3
Cat. No.: HY-P701391
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PSMG4; Proteasome assembly chaperone 4; PAC-4; HPAC4
Cat. No.: HY-181561
BRCA2-RAD51-IN-3 is a RAD51-BRCA2 protein-protein interaction inhibitor with an EC50 of 29.35 μM and a Kd of 75.14 μM. BRCA2-RAD51-IN-3 blocks RAD51-BRCA2 binding, impairs homologous recombination in cancer cells, and induces synthetic lethality. BRCA2-RAD51-IN-3 acts in human pancreatic cancer cells and shows no activity in normal pancreatic cells. BRCA2-RAD51-IN-3 can be used for the research of pancreatic cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
